Related Experiment Videos
Geldanamycin selectively destabilizes and conformationally alters mutated p53
M V Blagosklonny1, J Toretsky, L Neckers
1Clinical Pharmacology Branch, NCI, NIH, Bethesda, Maryland 20892, USA.
Oncogene
|September 7, 1995
Summary
Geldanamycin (GA) destabilizes mutated p53 proteins, reducing their levels and restoring DNA binding. This shows potential for pharmacologic intervention against mutated p53 in cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Mutated p53 proteins disrupt wild-type p53 function and act as oncogenes.
- Most p53 mutations lead to altered protein conformation and extended half-life.
Purpose of the Study:
- To investigate if geldanamycin (GA) can alter the stability and DNA binding of mutated p53 proteins.
- To assess GA's effect on both mutated and wild-type p53.
Main Methods:
- Treatment of cancer cell lines (breast, prostate, leukemia) with GA.
- Analysis of p53 protein levels, half-life, conformation, and DNA binding.
- Use of mutant conformation-specific and wild-type specific antibodies.
Main Results:
- GA significantly reduced mutated p53 levels and half-life in various cancer cell lines.
- GA did not affect wild-type p53 levels or inducibility.
- GA treatment restored partial wild-type DNA binding ability to mutated p53.
- GA altered mutated p53 conformation, making it undetectable by specific antibodies.
Conclusions:
- Geldanamycin effectively targets and destabilizes mutated p53 proteins.
- Pharmacologic intervention with GA shows promise for altering the mutated p53 phenotype in cancer treatment.